Neurocrine Biosciences, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: The election of the Board of Directors' three nominees for Class III directors named below to the Board of Directors to serve for a term of three years: Gary A. Lyons

Neurocrine Biosciences, Inc.’s own tally for this item (“Elect Director: Gary A. Lyons”): 75,278,705 for, 9,487,575 withheld, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The three nominees for Class III Director were elected.”
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 141 asset managers below reported 38,129,008 for, 2,117,901 withheld, 22 abstained, 98 not voted.

Showing the 25 largest of 141 asset managers. See all 141 in the interactive database.

Description as filed by funds: The election of the Board of Directors' three nominees for Class III directors named below to the Board of Directors to serve for a term of three years: Johanna Mercier

Neurocrine Biosciences, Inc.’s own tally for this item (“Elect Director: Johanna Mercier”): 74,671,942 for, 10,094,338 withheld, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The three nominees for Class III Director were elected.”
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 141 asset managers below reported 38,161,923 for, 2,084,987 withheld, 21 abstained, 98 not voted.

Showing the 25 largest of 141 asset managers. See all 141 in the interactive database.

Description as filed by funds: The election of the Board of Directors' three nominees for Class III directors named below to the Board of Directors to serve for a term of three years: Kevin C. Gorman, Ph.D.

Neurocrine Biosciences, Inc.’s own tally for this item (“Elect Director: Kevin C. Gorman, Ph.D.”): 76,228,063 for, 8,538,217 withheld, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The three nominees for Class III Director were elected.”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 141 asset managers below reported 38,129,009 for, 2,117,901 withheld, 21 abstained, 98 not voted.

Showing the 25 largest of 141 asset managers. See all 141 in the interactive database.

Description as filed by funds: To approve an amendment of the Company's 2025 Equity Incentive Plan to increase the aggregate number of shares of common stock reserved for issuance thereunder by 4,000,000 shares; and

The 143 asset managers below reported 39,184,889 for, 975,913 against, 18,713 abstained, 98 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 143 asset managers. See all 143 in the interactive database.

Description as filed by funds: Advisory vote on the compensation paid to the Company's named executive officers;

Neurocrine Biosciences, Inc.’s own tally for this item (“The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis. • Approval of the Amended 2025 Plan.”): 79,131,622 for, 5,568,926 against — passed, per its Form 8-K filed May 28, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 141 managers: 39,844,528 for, 388,206 against, 18,613 abstained, 98 not voted, 121 mixed. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 525 managers: 49,312,572 for, 4,568,635 against, 61,236 abstained, 12,691 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Neurocrine Biosciences, Inc.’s own tally for this item (“The Amended 2025 Plan was approved. • Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 83,880,185 for, 6,170,483 against — passed, per its Form 8-K filed May 28, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Amended 2025 Plan was approved.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 145 asset managers below reported 40,134,482 for, 150,201 against, 18,613 abstained, 98 not voted.

Showing the 25 largest of 145 asset managers. See all 145 in the interactive database.